Dose prescription and optimisation based on tumour hypoxia

References

• Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45–50
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31–9
   PubMed Web of Science ®Google Scholar
• Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113–7
   PubMed Web of Science ®Google Scholar
• Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28: 36–41
   PubMed Web of Science ®Google Scholar
• Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002; 20: 680–7
   PubMed Web of Science ®Google Scholar
• Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. Int J Radiat Oncol Biol Phys 2006; 65: 91–9
   PubMed Web of Science ®Google Scholar
• Hall EJ, Giaccia AJ. Radiobiology for the radiologist6^th ed. Lippincott Williams & Wilkins, Philadelphia 2006
   Google Scholar
• Watson ER, Halnan KE, Dische S, Saunders MI, Cade IS, McEwen JB, et al. Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978; 51: 879–87
   PubMed Web of Science ®Google Scholar
• Saunders MI, Hoskin PJ, Pigott K, Powell ME, Goodchild K, Dische S, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: A feasibility study. Radiother Oncol 1997; 45: 159–66
   PubMed Web of Science ®Google Scholar
• Kaanders JH, Pop LA, Marres HA, Liefers J, van den Hoogen FJ, van Daal WA, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998; 48: 115–22
   PubMed Web of Science ®Google Scholar
• Dische S. Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother Oncol 1985; 3: 97–115
   PubMed Web of Science ®Google Scholar
• Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994; 6: 509–18
   PubMed Web of Science ®Google Scholar
• Overgaard J, Horsman MR. Modification of Hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10–21
   PubMed Web of Science ®Google Scholar
• Fowler JF. Nuclear particles in cancer treatment. Adam Hilger Ltd, Bristol 1981
   Google Scholar
• Brahme A. Recent advances in light ion radiation therapy. Int J Radiat Oncol Biol Phys 2004; 58: 603–16
   PubMed Web of Science ®Google Scholar
• Lind BK, Brahme A. The radiation response of heterogeneous tumors. Phys Med 2007; 23: 91–9
   PubMedGoogle Scholar
• Daşu A, Toma-Daşu I. Vascular oxygen content and the tissue oxygenation–a theoretical analysis. Med Phys 2008; 35: 539–45
   PubMed Web of Science ®Google Scholar
• Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49(Suppl 2)129S–148
   PubMed Web of Science ®Google Scholar
• Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000; 47: 551–60
   PubMed Web of Science ®Google Scholar
• Tome WA, Fowler JF. On the inclusion of proliferation in tumour control probability calculations for inhomogeneously irradiated tumours. Phys Med Biol 2003; 48: N261–N268
   PubMedGoogle Scholar
• Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 1171–82
   PubMed Web of Science ®Google Scholar
• Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 541–51
   PubMed Web of Science ®Google Scholar
• Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007; 37: 451–61
   PubMed Web of Science ®Google Scholar
• Xing L, Cotrutz C, Hunjan S, Boyer AL, Adalsteinsson E, Spielman D. Inverse planning for functional image-guided intensity-modulated radiation therapy. Phys Med Biol 2002; 47: 3567–78
   PubMedGoogle Scholar
• Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003; 48: N31–N35
   PubMed Web of Science ®Google Scholar
• Das SK, Miften MM, Zhou S, Bell M, Munley MT, Whiddon CS, et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004; 31: 1452–61
   PubMed Web of Science ®Google Scholar
• Malinen E, Sovik A, Hristov D, Bruland OS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006; 51: 4903–21
   PubMed Web of Science ®Google Scholar
• Søvik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: A modelling study. Phys Med Biol 2007; 52: 499–513
   PubMed Web of Science ®Google Scholar
• Flynn RT, Bowen SR, Bentzen SM, Rockwell MT, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008; 53: 4153–67
   PubMed Web of Science ®Google Scholar
• Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391–8
   PubMed Web of Science ®Google Scholar
• Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?. Acta Oncol 2008; 47: 1237–48
   PubMed Web of Science ®Google Scholar
• Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007; 68: 291–300
   PubMed Web of Science ®Google Scholar
• Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol 2003; 42: 123–36
   PubMed Web of Science ®Google Scholar
• Douglas BG, Fowler JF. Fractionation schedules and a quadratic dose-effect relationship. Br J Radiol 1975; 48: 502–4
   PubMed Web of Science ®Google Scholar
• Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 1981–97
   PubMed Web of Science ®Google Scholar
• Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679–94
   PubMed Web of Science ®Google Scholar
• Alper T, Howard-Flanders P. Role of oxygen in modifying the radiosensitivity of E. Coli B. Nature 1956; 178: 978–9
   PubMed Web of Science ®Google Scholar
• Alper T. Cellular radiobiology. Cambridge University Press, Cambridge 1979
   Google Scholar
• Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990; 19: 219–35
   PubMed Web of Science ®Google Scholar
• Ågren Cronqvist AK, Kallman P, Turesson I, Brahme A. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours. Acta Oncol 1995; 34: 851–60
   PubMed Web of Science ®Google Scholar
• Brahme A, Ågren AK. Optimal dose distribution for eradication of heterogeneous tumours. Acta Oncol 1987; 26: 377–85
   PubMed Web of Science ®Google Scholar
• Ljungkvist ASE, Bussink J, Rijken PFJW, Kaanders JHAM, van der Kogel AJ, Denekamp J. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2002; 54: 215–28
   PubMed Web of Science ®Google Scholar
• Daşu A, Toma-Daşu I, Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys Med Biol 2003; 48: 2829–42
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Brady M. A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data. Phys Med Biol 2006; 51: 5859–73
   PubMed Web of Science ®Google Scholar
• Brahme A. Dosimetric precision requirements and quantities for characterizing the response of tumors and normal tissues. IAEA-TECDOC 1996; 896: 49–65
   Google Scholar
• Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol 1984; 23: 379–91
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449–65
   PubMed Web of Science ®Google Scholar
• Daşu A, Toma-Daşu I. Theoretical simulation of tumour oxygenation – practical applications. Adv Exp Med Biol 2006; 578: 357–62
   PubMedGoogle Scholar
• Toma-Daşu I, Daşu A, Brahme A. Quantifying tumour hypoxia by PET imaging – a theoretical analysis. Adv Exp Med Biol 2009; 645: 267–72
   PubMed Web of Science ®Google Scholar
• Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638–48
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007; 25: 4066–74
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 1987; 47: 597–601
   PubMed Web of Science ®Google Scholar
• Bussink J, Kaanders JHAM, Rijken PFJW, Peters JPW, Hodgkiss RJ, Marres HAM, et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide. Radiother Oncol 1999; 50: 173–83
   PubMed Web of Science ®Google Scholar
• Rijken PFJW, Bernsen HJJA, Peters JPW, Hodgkiss RJ, Raleigh JA, van der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: A quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000; 48: 571–82
   PubMed Web of Science ®Google Scholar
• Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007; 83: 406–10
   PubMed Web of Science ®Google Scholar
• Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984; 54: 2441–9
   PubMed Web of Science ®Google Scholar
• Toma-Daşu, I, Uhrdin, J, Daşu, A, Brahme, A. Therapy optimization based on non-linear uptake of PET tracers versus “linear dose painting”. IFMBE Proceedings 2009, in press
   PubMedGoogle Scholar
• Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177–83
   PubMed Web of Science ®Google Scholar
• Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072–9
   PubMed Web of Science ®Google Scholar
• Wijffels KI, Kaanders JH, Rijken PF, Bussink J, van den Hoogen FJ, Marres HA, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 2000; 83: 674–83
   PubMed Web of Science ®Google Scholar
• Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004; 180: 616–22
   PubMed Web of Science ®Google Scholar
• O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493–502
   PubMed Web of Science ®Google Scholar
• Toma-Daşu I, Daşu A, Waites A, Denekamp J, Fowler JF. Theoretical simulation of oxygen tension measurement in the tissue using a microelectrode: II. Simulated measurements in tissues. Radiother Oncol 2002; 64: 109–18
   PubMedGoogle Scholar
• Toma-Daşu I, Daşu A, Karlsson M. The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiation. Phys Med Biol 2004; 49: 4463–75
   PubMed Web of Science ®Google Scholar
• Daşu A. Treatment planning optimisation based on imaging tumour proliferation and cell density. Acta Oncol 2008; 47: 1221–8
   PubMed Web of Science ®Google Scholar